Washington State Health Advocacy Association (WASHAA)
  • Home
  • About Us
    • Board of Directors & Staff
    • Sponsors & Partners
  • Patients & Caregivers
    • COVID-19 Resources for Individuals & Families
    • Who Needs a Health Advocate?
    • Who is a Health Advocate
    • Types of Health Advocacy Services
    • Find a Health Advocate
    • Resources
  • Professionals & Partners
    • COVID-19 Resources for Advocates
    • Tools and Resources >
      • Presentation Training
      • Health Care Proxy Package
      • Online CEUs
    • Become a Member
    • Member Login
    • Online CEUs
  • Events | Webinars | Presentations
    • Upcoming Events
    • Webinars >
      • Past Webinars
    • Presentations >
      • Request a Presentation
    • Calendar
    • Online CEUs
  • News
    • Monthly eNewsletters
    • WASHAA in the News
    • Advocacy in the News
    • Podcasts
    • Blog
  • Get Involved!
    • Make a Donation
    • Become a WASHAA Member
    • Volunteer
    • Share Your Story
  • Contact Us
  • Community Conversations About COVID-19

Right to try-act

8/29/2017

0 Comments

 
By Hartmut Stecher, PhD, MS
Principal Scientist at Cancer Treatment Navigator, Inc.
Picture
​Patient access to investigational cancer drugs is governed by the FDA, via clinical trials and the compassionate use program. The new senate approved bill “Right to Try Act”, provides a third new avenue to patients to secure investigational drug. The pros and cons about the “Right to Try Act” are debated in this Medpage article.
Cancer Treatment Navigator (CTN) has intimate perspective on issues faced by cancer patients in accessing investigational therapies. Our personalized services identify treatments not yet considered for cancer patients diagnosed at any stage, after a complete review of their medical history and gene mutation profile. Often, these turn out to be drugs under study in clinical trials, and not available in clinics or hospital formularies. In our experience, patients continue to face difficulty in accessing these drugs because of factors such as physician opinion on when to keep trying and when to give up hope of improving a patient’s condition. Several hopeful patients that make informed choices on wanting to try an investigational therapy end up battling odds when their cancer care team, led by an Oncologist is unaligned on the benefit/risk profile of a drug that is in clinical trials, even though there is ample safety data to warrant its use.

One of the patients we served in the past had highly metastatic throat cancer. Scientific and clinical data supported that he might greatly benefit from a drug that is approved for a special form of lymphoma. This specific drug was “investigational” for metastatic throat cancer, yet had been on the market for lymphoma for almost a decade – with thousands of patients treated and a remarkable safety record. Yet, it was the Oncologist’s decision to refuse writing a prescription for this drug, citing concerns about the patient’s safety. The irony of this story was the fact that the Oncologist did sign the paperwork for “Death with Dignity”, but could not honor the wish of the patient to try one last “investigational” option with established safety before giving up.

This is one of the cases where CTN wholeheartedly supports a “Right to Try-Law”, with provisions to truly empower patients. We would have worked hard for this patient to secure insurance coverage for this investigational drug or work directly with the manufacturer to gain access to this medicine. Above all, the patient would have been willing to pay for a 2-month supply out of pocket – enough to assess if the drug is providing benefit – and still not too long that the patient and his family would have encountered financial hardship. The only “missing link” to gain access to this investigational drug was the signature of the Oncologist on the prescription. It should be the patient’s decision to try one more time, and not of one individual Oncologist. Oncologists play a pivotal role in providing proven therapies, but often do not have the bandwidth to research and assess numerous investigational drugs or get lost in paperwork and phone calls to try secure coverage of investigational drugs. In its current form, will the “Right to try Act” be able to make a difference? We believe there should be modifications on how to assess safety before it is passed into law, so that Oncologists have to define why they don’t accept an investigational drug’s safety, instead of a mere “yes” and “no” based on comfort level dictating a cancer patients right to try.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    August 2019
    February 2019
    September 2018
    October 2017
    August 2017
    January 2017
    November 2016
    November 2015
    October 2015
    August 2015
    July 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    November 2013
    July 2013

    Categories

    All
    Events
    Health Advocacy
    Local Advocacy – Awareness Partnerships
    Newsletters
    Washaa News


      Volunteer!

      Make your selection here. Which committee would you like to join?

    Submit

    RSS Feed

About Us
What is WASHAA?
Code of Ethics
Event Calendar
Professionals & Members
Careers
​
Become a Member

Member Login
Patients & Caregivers
Who Needs a Health Advocate
Who is a Health Advocate
Types of Health Advocacy

Find a Health Advocate


Legal
Privacy Policy
Terms of Use
Email us at info@washaa.org or call us at 206.377.3000
© 2008-2020 WASHAA. All Rights Reserved. 
WASHAA is a 501(c)(3) organization and a registered charity in WA State | Federal EIN: 45-5441201